JP2012521769A5 - - Google Patents

Download PDF

Info

Publication number
JP2012521769A5
JP2012521769A5 JP2012502309A JP2012502309A JP2012521769A5 JP 2012521769 A5 JP2012521769 A5 JP 2012521769A5 JP 2012502309 A JP2012502309 A JP 2012502309A JP 2012502309 A JP2012502309 A JP 2012502309A JP 2012521769 A5 JP2012521769 A5 JP 2012521769A5
Authority
JP
Japan
Prior art keywords
tumor
cells
cell population
initiating
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012502309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521769A (ja
JP5788863B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/028926 external-priority patent/WO2010111659A1/en
Publication of JP2012521769A publication Critical patent/JP2012521769A/ja
Publication of JP2012521769A5 publication Critical patent/JP2012521769A5/ja
Application granted granted Critical
Publication of JP5788863B2 publication Critical patent/JP5788863B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012502309A 2009-03-27 2010-03-26 腫瘍開始細胞およびその使用方法 Expired - Fee Related JP5788863B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16427209P 2009-03-27 2009-03-27
US61/164,272 2009-03-27
PCT/US2010/028926 WO2010111659A1 (en) 2009-03-27 2010-03-26 Tumor-initiating cells and methods for using same

Publications (3)

Publication Number Publication Date
JP2012521769A JP2012521769A (ja) 2012-09-20
JP2012521769A5 true JP2012521769A5 (cg-RX-API-DMAC7.html) 2013-05-23
JP5788863B2 JP5788863B2 (ja) 2015-10-07

Family

ID=42332716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012502309A Expired - Fee Related JP5788863B2 (ja) 2009-03-27 2010-03-26 腫瘍開始細胞およびその使用方法

Country Status (6)

Country Link
US (2) US9340774B2 (cg-RX-API-DMAC7.html)
EP (1) EP2411508B1 (cg-RX-API-DMAC7.html)
JP (1) JP5788863B2 (cg-RX-API-DMAC7.html)
CA (1) CA2754610C (cg-RX-API-DMAC7.html)
ES (1) ES2405605T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010111659A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031017T2 (en) 2011-04-01 2017-06-28 Wyeth Llc Antibody Drug Conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
US10254286B2 (en) 2012-01-24 2019-04-09 Pfizer Inc. Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
US9551036B2 (en) * 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
US9476100B1 (en) * 2015-07-06 2016-10-25 Nucleix Ltd. Methods for diagnosing bladder cancer
KR20190105028A (ko) 2017-01-04 2019-09-11 내셔널 타이완 유니버시티 폐암 줄기 세포를 위한 바이오마커
EP3595705A1 (en) * 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Method
CA3078791A1 (en) 2017-10-11 2019-04-18 Lunella Biotech, Inc. Anti-mitochondrial inhibitors for oncogenic ras and myc
US11189361B2 (en) 2018-06-28 2021-11-30 International Business Machines Corporation Functional analysis of time-series phylogenetic tumor evolution tree
US11211148B2 (en) 2018-06-28 2021-12-28 International Business Machines Corporation Time-series phylogenetic tumor evolution trees
IL265451B (en) 2019-03-18 2020-01-30 Frumkin Dan Methods and systems for the detection of methylation changes in DNA samples
CN114487418A (zh) 2022-02-17 2022-05-13 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) TGFb RIII蛋白作为胃癌血清生物标志物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
DE68923027D1 (de) 1988-03-04 1995-07-20 Cancer Res Campaign Tech Antigene.
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
GB0215287D0 (en) * 2002-07-02 2002-08-14 Oxford Biomedica Ltd 5T4 antigen expression
CA2578131A1 (en) 2004-09-10 2006-03-23 Wyeth Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
EP1945754B1 (en) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
SG170091A1 (en) 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
Tang et al. Exosomes: Emerging biomarkers and targets for ovarian cancer
Nakata et al. Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells
EP3009454A3 (en) Antibodies specific to cadherin-17
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
WO2016081748A3 (en) Antibodies against cd73 and uses thereof
Wu et al. Extracellular vesicles in urologic malignancies—Implementations for future cancer care
CL2012002700A1 (es) Anticuerpo humanizado capaz de logarse especificamente a receptores de quimioquina 4 (cxcr4); molecula de acido nucleico aislada que codifica dicho anticuerpo; vector y célula que comprenden dicho acido nucleico; composicion que comprende dicho anticuerpo; proceso de deteccion in vitro de la presencia y/o la ubicacion de un tumor que expresa cxcr4.
US10081793B2 (en) Method for separating cells using immunorosettes and magnetic particles
RU2013124412A (ru) Покрытые графеном алмазные частицы, композиции и промежуточные структуры, содержащие такие частицы, и способы формирования покрытых графеном алмазных частиц и поликристаллических элементов
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
WO2012054084A3 (en) Antibodies
PL2313201T3 (pl) Selektywne rozdzielanie materiałów za pomocą zmodyfikowanych cząstek magnetycznych
JP2015506926A5 (cg-RX-API-DMAC7.html)
IN2012DN00834A (cg-RX-API-DMAC7.html)
MX2009005776A (es) Anticuerpos humanos que se enlazan al cd 22 y sus usos.
JP2017536114A5 (cg-RX-API-DMAC7.html)
CN103436493B (zh) 雷帕霉素诱导调节性γδT细胞的培养方法
MX2022007613A (es) Union de anticuerpos de cadena pesada a cd38.
UA102891C2 (uk) Повні людські антитіла, специфічні до cadm1
CN114174829A (zh) T细胞受体的选择
AR089028A1 (es) Composiciones y metodos para el analisis de cancer de prostata
Soltanian et al. Kaempferol and docetaxel diminish side population and down-regulate some cancer stem cell markers in breast cancer cell line MCF-7
EA201400065A1 (ru) Антитела
CN108398560A (zh) 一种cd133质谱流式抗体、制备方法及应用
BR112015014270A2 (pt) co-diferenciação de monócitos a partir de doadores alogênicos